A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro

Biochemical and Biophysical Research Communications

Volumn 411, Issue 3, 2011, Pages 530-535

  Han, Hui ^a   Peng, Ji Run ^a   Chen, Peng Cheng ^a   Gong, Lei ^a   Qiao, Shi Shi ^b   Wang, Wen Zhen ^a   Cui, Zhu Qingqing ^a   Yu, Xin ^a   Wei, Yu Hua ^a   Leng, Xi Sheng ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Adoptive immunotherapy; Artificial antigen presenting cells; Controlled release; Cytotoxic T lymphocytes; Interleukin 2

Indexed keywords

AVIDIN; BIOTIN; FLU ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN; MICROSPHERE; POLYGLACTIN; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; ARTIFICIAL ANTIGEN PRESENTING CELL; ARTIFICIAL CELL; BINDING AFFINITY; BINDING KINETICS; BIOTINYLATION; CD8+ T LYMPHOCYTE; CELL EXPANSION; CHEMICAL MODIFICATION; CONJUGATE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EMULSION; ENCAPSULATION; ENZYME LINKED IMMUNOSPOT ASSAY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA A; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOLECULAR RECOGNITION; PARTICLE SIZE; PRIORITY JOURNAL; SURFACE PROPERTY;

ANTIGEN-PRESENTING CELLS; ARTIFICIAL CELLS; AVIDIN; BIOTIN; BIOTINYLATION; CAPSULES; ENZYME-LINKED IMMUNOSPOT ASSAY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; LACTIC ACID; LIGANDS; LYMPHOCYTE ACTIVATION; MICROSPHERES; PEPTIDE FRAGMENTS; POLYGLYCOLIC ACID; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

EID: 79961127804     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.164     Document Type: Article

References (28)

1. Oosten L.E., Koppers-Lalic D., Blokland E., Mulder A., Ressing M.E., Mutis T., van Halteren A.G., Wiertz E.J., Goulmy E. TAP-inhibiting proteins US6, ICP47 and UL49.5 differentially affect minor and major histocompatibility antigen-specific recognition by cytotoxic T lymphocytes. Int. Immunol. 2007, 19:1115-1122.
2. + T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity. J. Immunol. 2007, 179:5534-5542.
3. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 2008, 8:299-308.
4. Pegram H.J., Jackson J.T., Smyth M.J., Kershaw M.H., Darcy P.K. Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J. Immunol. 2008, 181:3449-3455.
5. Dudley M.E., Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 2003, 3:666-675.
6. Pardoll D.M. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2002, 2:227-238.
7. Mescher M.F., Curtsinger J.M., Agarwal P., Casey K.A., Gerner M., Hammerbeck C.D., Popescu F., Xiao Z. Signals required for programming effector and memory development by CD8+ T cells. Immunol. Rev. 2006, 211:81-92.
8. Mackensen A., Meidenbauer N., Vogl S., Laumer M., Berger J., Andreesen R. Phase I study of adoptive T cells therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 2006, 24:5060-5069.
9. Fiore F., Castella B., Nuschak B., Bertieri R., Mariani S., Bruno B., Pantaleoni F., Foglietta M., Boccadoro M., Massaia M. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 2007, 110:921-927.
10. Milone M.C., June C.H. Adoptive immunotherapy: new ways to skin the cat?. Clin. Immunol. 2005, 117:101-103.
11. Kim J.V., Latouche J., Rivière I., Sadelain M. The ABCs of artificial antigen presentation. Nat. Biotechnol. 2004, 22:403-410.
12. Kim S.H., Bianco N.R., Shufesky W.J., Morelli A.E., Robbins P.D. Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4. J. Immunol. 2007, 179:2242-2249.
13. Cobbold M., Khan N., Pourgheysari B., Tauro S., McDonald D., Osman H., Assenmacher M., Billingham L., Steward C., Crawley C., Olavarria E., Goldman J., Chakraverty R., Mahendra P., Craddock C., Moss P.A. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 2005, 202:379-386.
14. Oelke M., Maus M.V., Didiano D., June C.H., Mackensen A., Schneck J.P. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med. 2003, 9:619-624.
15. Oelke M., Krueger C., Giuntoli R.L., Schneck J.P. Artificial antigen-presenting cells: artificial solutions for real diseases. Trends Mol. Med. 2005, 11:412-420.
16. Zappasodi R., Di Nicola M., Carlo-Stella C., Mortarini R., Molla A., Vegetti C., Albani S., Anichini A., Gianni A.M. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. Haematologica 2008, 93:1523-1534.
17. Assier E., Jillien V., Lefort J., Moreau J.L., Di Santo J.P., Vargaftig B.B., Lapa e Silva J.R., Thèze J. NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome. J. Immunol. 2004, 172:7661-7668.
18. Steenblock E.R., Fahmy T.M. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol. Ther. 2008, 16:765-772.
19. Cheng J., Teply B.A., Sherifi I., Sung J., Luther G., Gu F.X., Levy-Nissenbaum E., Radovic-Moreno A.F., Langer R., Farokhzad O.C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28:869-876.
20. Huang A., Huang L., Kennel S.J. Monoclonal antibody covalently coupled with fatty acid. A reagent for in vitro liposome targeting. J. Biol. Chem. 1980, 255:8015-8018.
21. Feng L., Qi X.R., Zhou X.J., Maitani Y., Wang S.C., Jiang Y., Nagai T. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J. Control. Release 2006, 112:35-42.
22. Rognan D., Zimmermann N., Jung G., Folkers G. Molecular dynamics study of a complex between the human histocompatibility antigen HLA-A2 and the IMP58-66 nonapeptide from influenza virus matrix protein. Eur. J. Biochem. 1992, 208:101-113.
23. Sharifi A.M., Mousavi S.H., Bakhshayesh M., Tehrani F.K., Mahmoudian M., Oryan S. Study of correlation between lead-induced cytotoxicity and nitric oxide production in PC12 cells. Toxicol. Lett. 2005, 160:43-48.
24. Chaudhri G., Panchanathan V., Bluethmann H., Karupiah G. Obligatory requirement for antibody in recovery from a primary poxvirus infection. J. Virol. 2006, 80:6339-6344.
25. Zhuang X., Ha T., Kim H.D., Centner T., Labeit S., Chu S. Fluorescence quenching: a tool for single-molecule protein-folding study. Proc. Natl. Acad. Sci. USA 2000, 97:14241-14244.
26. Horowitz A., Li X., Poles M.A., Tsuji M. Use of immobilized HLA-A2:Ig dimeric proteins to determine the level of epitope-specific, HLA-restricted CD8+ T-cell response. Scand. J. Immunol. 2009, 70:415-422.
27. Deeths M.J., Mescher M.F. B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+ and CD8+ T cells. Eur. J. Immunol. 1997, 27:598-608.
28. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., Wunderlich J., Restifo N.P., Thomasian A., Downey S.G., Smith F.O., Klapper J., Morton K., Laurencot C., White D.E., Rosenberg S.A. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008, 26:5233-5239.